�Palatin Technologies,
Inc. (Amex: PTN) proclaimed the completion of a Phase 2a clinical
trial of PL-3994, a novel, long-acting natriuretic peptide sensory receptor A
(NPRA) agonist below development for treatment of heart failure (HF). The
Phase 2a trial was a randomised, double-blind, placebo-controlled, single
ascension dose survey in 21 volunteers with controlled high blood pressure who
received the medication or placebo subcutaneously. The purpose of the sketch
was to demonstrate that PL-3994 can be disposed safely to patients taking
antihypertensive medications commonly administered to heart failure and
hypertension patients. The evaluations included safety, tolerability,
pharmacokinetics and several pharmacodynamic endpoints, including levels of
cyclic guanosine monophosphate (cGMP), a natural messenger nucleotide.
Dosing concluded with the successful achievement of the primary
endpoint of the cogitation, a pre-specified reduction in systemic blood line
pressure. No volunteer experienced a serious or severe adverse upshot.
Elevations in plasma cGMP levels were all ascertained for several hours after
single subcutaneous doses. Additional data analysis is ongoing and volition be
submitted for intro when the analysis is complete.
"We are excited to confirm that PL-3994 can be given safely to patients
who ar taking blood pressure medications," stated Dr. Trevor Hallam,
Palatin's Executive Vice President for Research and Development. "As we
proceed with an additional Phase 2 study later this twelvemonth, we volition focus on
the ticker failure patients most in need of new therapies."
The previously announced Phase 1 study demonstrated that PL-3994 tin can be
granted safely and leads to a dose-related decrease in blood insistency and
increase in cGMP levels, diuresis (kidney evacuation of water) and
natriuresis (kidney evacuation of sodium). The data from this first study
has been accepted for presentation at the 12th Annual Scientific Meeting of
the Heart Failure Society of America to be held in Toronto, Canada on
September 21-24, 2008.
About Heart Failure (HF)
Currently in the U.S., HF affects nearly 5 one thousand thousand people with 550,000
new cases of HF diagnosed each year. Despite the intervention of HF with
multiple drugs, nigh all HF patients will experience at least one episode
of acute HF that requires treatment with intravenous medications in the
hospital. There were all over 1.1 million hospitalizations for HF in 2004.
Heart failure has frightful human and financial costs. Estimated direct
costs in the U.S. for HF were $29.6 zillion in 2006.
About Palatin Technologies, Inc.
Palatin Technologies, Inc. is a biopharmaceutical party dedicated to
the exploitation of proprietorship peptide, peptide mimetic and small mote
agonist compounds with a focus on melanocortin and natriuretic peptide
receptor systems. The melanocortin system is involved in a large and
divers number of physiologic functions, and therapeutic agents modulating
this system may have the potential drop to plow a variety of conditions and
diseases, including intimate dysfunction, fleshiness and related disorders,
ischemia and reperfusion injury, haemorrhagic shock and inflammation-related
diseases. The natriuretic peptide receptor system has numerous
cardiovascular functions, and therapeutic agents modulating this system whitethorn
be useful in treatment of heart failure, high blood pressure and other
cardiovascular diseases. Palatin's strategy is to develop products and then
form marketing collaborations with industry leadership in order to maximize
their commercial-grade potential. The Company presently has collaborations with
AstraZeneca and the Mallinckrodt division of Covidien. For additional
information regarding Palatin, please visit Palatin Technologies' website
at hhttp://www.palatin.com
Forward looking Statements
Statements about the Company's future expectations, including
statements about its development programs, proposed indications for its
product candidates, pre-clinical activities, clinical activities, marketing
collaborations, and all other statements in this document other than
diachronic facts, ar "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, Section 21E of the Securities
Exchange Act of 1934 and as that term is defined in the Private Securities
Litigation Reform Act of 1995. The Company intends that such
forward-looking statements shall be case to the safe harbors created
thereby. Palatin's factual results may differ materially from those
discussed in the forrard looking statements for versatile reasons,
including, but non limited to the Company's ability to fund development of
its technology, ability to establish and successfully complete clinical
trials and pre-clinical studies and the results of those trials and
studies, dependence on its partners for certain development activities,
need for regulatory approvals and commercial acceptance of its products,
ability to recommence marketing and realise commercial acceptance of
NeutroSpec(R), ability to protect its intellectual property, and other
factors discussed in the Company's periodic filings with the Securities and
Exchange Commission. The Company is not responsible for updating for events
that come about after the date of this compress release.
Palatin Technologies, Inc.
http://www.palatin.com
More info
Wednesday 3 September 2008
Sunday 24 August 2008
Research On Nanoparticles And Human Health At University Of Kentucky Receives $2M Grant
�The U.S. Environmental Protection Agency (EPA) has proclaimed the award of a $2 million grant to the University of Kentucky (UK) to investigate how the sizes and shapes of nanoparticles affect their ability to enter the brain. This is the largest EPA Science to Achieve Results (STAR) grant ever awarded to the University of Kentucky as well as the largest single assignment ever awarded by EPA STAR for nanotechnology research.
"Nanotechnology is an exciting new field with the potential to transform environmental auspices," said Russell L. Wright, Jr., Deputy Regional Administrator (Acting) for EPA Region 4 in Atlanta, Ga. "With nanomaterial use increasing every sidereal day across industries from health care to fabrication, it is essential that we sympathise the implications of nanotechnology for human health and the environment."
"I applaud Dr. Yokel and his research team for earning such a esteemed award," aforesaid UK President Lee T. Todd, Jr. "It is an honour that the EPA STAR program selected UK for the largest single subsidization it has ever awarded for nanotechnology research. This award is a perfect example of why it is so important that Kentucky has a foremost research university, as it shows that the stellar faculty and researchers that we have been able to recruit and retain here at UK ar among the best in the world."
The research team, led by Dr. Robert Yokel, will study potentiality health impacts of nano-sized cerium oxide, a diesel engine fuel linear. Used currently in Europe, it is claimed to improve fire efficiency, suppress soot from exhaust, and reduce the concentration of other ultra-fine particles in air that have known health personal effects. The research project will be funded for 4 years.
Nanotechnology is the skill of manipulating extremely small particles - ranging in size from 1 to 100 nanometers. The physical, chemical, electronic, and optical properties of these nanoparticles may be different from the larger form of the same material. As such, nanomaterials may hold unique impacts on the environment and human health.
As nanotechnology progresses from inquiry and development to commercialisation and use, it is likely that manufactured nanomaterials will be released into the surround. EPA is charged with protecting human health and the environment, as well as ensuring that the uses of engineered nanotechnology products come without excessive harm to human health or the environment. This research testament provide relevant information requisite for jeopardy assessments that can inform decision-making related to nanotechnology products.
To study more around EPA's nanotechnology program: http://www.epa.gov/ncer/nano
Click here for more info on this grant.
Source: Laura Niles
U.S. Environmental Protection Agency
More info
"Nanotechnology is an exciting new field with the potential to transform environmental auspices," said Russell L. Wright, Jr., Deputy Regional Administrator (Acting) for EPA Region 4 in Atlanta, Ga. "With nanomaterial use increasing every sidereal day across industries from health care to fabrication, it is essential that we sympathise the implications of nanotechnology for human health and the environment."
"I applaud Dr. Yokel and his research team for earning such a esteemed award," aforesaid UK President Lee T. Todd, Jr. "It is an honour that the EPA STAR program selected UK for the largest single subsidization it has ever awarded for nanotechnology research. This award is a perfect example of why it is so important that Kentucky has a foremost research university, as it shows that the stellar faculty and researchers that we have been able to recruit and retain here at UK ar among the best in the world."
The research team, led by Dr. Robert Yokel, will study potentiality health impacts of nano-sized cerium oxide, a diesel engine fuel linear. Used currently in Europe, it is claimed to improve fire efficiency, suppress soot from exhaust, and reduce the concentration of other ultra-fine particles in air that have known health personal effects. The research project will be funded for 4 years.
Nanotechnology is the skill of manipulating extremely small particles - ranging in size from 1 to 100 nanometers. The physical, chemical, electronic, and optical properties of these nanoparticles may be different from the larger form of the same material. As such, nanomaterials may hold unique impacts on the environment and human health.
As nanotechnology progresses from inquiry and development to commercialisation and use, it is likely that manufactured nanomaterials will be released into the surround. EPA is charged with protecting human health and the environment, as well as ensuring that the uses of engineered nanotechnology products come without excessive harm to human health or the environment. This research testament provide relevant information requisite for jeopardy assessments that can inform decision-making related to nanotechnology products.
To study more around EPA's nanotechnology program: http://www.epa.gov/ncer/nano
Click here for more info on this grant.
Source: Laura Niles
U.S. Environmental Protection Agency
More info
Thursday 14 August 2008
Coldplay adds new dates to North American tour
Coldplay [ ] has added a few new shows to the North American stage of the world circuit in backup of the band's up-to-the-minute chart-topping studio apartment album.
The British alt-rockers, world Health Organization are presently enjoying a brief reveal from the road after finishing off an initial block of summer dates last week, will plain off the next stretch out of American shows Oct. 20 in Ottawa, Ontario. New dates since last check include fresh additions in Boston (10/29); Washington, DC (10/31); Philadelphia (11/1) and Atlanta (11/5). Details are below.
story_top_holder>
The band will also mount a European run in September; those dates can be plant at Coldplay's website.
"Viva La Vida or Death and All His Friends," Coldplay's fourth studio record album, debuted at No. 1 after its June discharge, moving more than 720,000 units in the US alone, 288,000 of which were digital downloads, according to Billboard, which claimed it was the best ever sales week for a digital album.
The album, which was produced by Brian Eno and Markus Dravs, scored equally well in the band's plate country, merchandising more than 300,000 copies in its first base week stunned in the UK.
The young record follows Coldplay's 2005 Grammy-nominated set, "X&Y," which entered The Billboard cc at No. 1 and has since sold more than 10 million copies on the strength of hits including "Talk," "Fix You" and "Speed of Sound."
[Note: The following spell dates have been provided by creative person and/or tour sources, wHO verify its accuracy as of the publication time of this story. Changes may take place before go on cut-rate sale. Check with official creative person websites, ticketing sources and venues for late updates.]
October 200820 - Ottawa, Ontario - Scotiabank Place21 - Cleveland, OH - Quicken Loans Arena26, 27 - East Rutherford, NJ - IZOD Center29 - Boston, MA - TD Banknorth Garden31 - Washington, DC - Verizon CenterNovember 20081 - Philadelphia, PA - Wachovia Center3 - Auburn Hills, MI - Palace of Auburn Hills5 - Atlanta, GA - Phillips Arena7 - Orlando, FL - Amway Arena9 - Sunrise, FL - BankAtlantic Center11 - Atlanta, GA - Philips Arena13 - Kansas City, MO - Sprint Center14 - St. Paul, MN - Xcel Energy Center16 - Oklahoma City, OK - Ford Center18 - Houston, TX - Toyota Center19 - Dallas, TX - American Airlines Center21 - Denver, CO - Pepsi Center Arena22 - Salt Lake City, UT - Energy Solutions Arena26 - Glendale, AZ - Jobing.com Arena
More info
Wednesday 6 August 2008
Ruthless and Vorwerk
Artist: Ruthless and Vorwerk
Genre(s):
Other
Discography:
Splendid
Year: 2006
Tracks: 3
Sonny Boy Williamson II
Friday 27 June 2008
Move Over, Clay: Ruben's Got a New Tag-Team Partner
Looks like the Velvet Teddy Bear has found a long-term snuggle bunny.
American Idol season-two champ Ruben Studdard obtained a marriage license in his hometown of Birmingham, Ala.,...
Thursday 19 June 2008
'Bucket List' tops sales, rentals
Fox's 'Jumper' debuts a close second
Warner Home Video's "The Bucket List" was the top video seller and renter for the week ending June 15, while fellow new release "Jumper," from Fox, topped the Blu-ray Disc sales chart.
"Bucket," a comedy that generated $93.5 million at the U.S. boxoffice, debuted at No. 1 on the Nielsen VideoScan First Alert sales chart and Home Media Magazine's video rental chart.
"Jumper," a sci-fi actioner with $79.9 million in theatrical receipts, bowed at a close No. 2 on the sales chart, selling 88% as many units as "Bucket List." The film also debuted at No. 2 on the rental chart, generating 91.5% as much action at the rental counter as the Warner comedy.
Two other new releases debuted in the First Alert top 10: Sony Pictures' "The Other Boleyn Girl," a historical drama, at No. 4, and HBO's critically hailed "John Adams" documentary miniseries at No. 5.
"Boleyn Girl," which made $26.8 million at the boxoffice, also scored big with renters, debuting at No. 6 on the Home Media Magazine chart.
Several older releases continued to maintain steady sales. Two Paramount "Indiana Jones" DVDs, "Raiders of the Lost Ark" (No. 7) and "Indiana Jones and the Last Crusade" (No. 9), remained in the First Alert top 10 five weeks after their release, which coincided with the theatrical debut of the new "Indiana Jones" movie. So did "Indiana Jones -- The Adventure Collection" (No. 8), a boxed set with all three earlier films.
See Also
Friday 6 June 2008
Miami Rolls Out the Red Carpet for Latin Star Studded FedEx/St. Jude Gala
Join Daisy Fuentes in honoring Emilio and Gloria Estefan at the event to
benefit St. Jude
Live performances by Luis Fonsi, Jeremias, and Valeria Gastaldi
MIAMI, May 9 -- St. Jude Children's Research Hospital(R),
the world's premier pediatric cancer research and treatment center,
celebrates its sixth annual FedEx/St. Jude Angels & Stars Gala on Saturday,
May 17, at the Adrienne Arsht Center for the Performing Arts of Miami-Dade
County.
(Photo: http://www.newscom.com/cgi-bin/prnh/20080509/CLF029 )
Latin stars join Daisy Fuentes in honoring Emilio and Gloria Estefan
for their commitment to international healthcare, the local community and
their presence in the music and entertainment industry.
"We are overwhelmed with pride to be honored by such an esteemed
group," said Gloria Estefan. "We are especially grateful for the hospital's
life saving efforts throughout Latin America. The St. Jude International
Outreach Program offers hope for sick children and their families, and they
also share their medical knowledge with the doctors who treat these
children in their hometowns and villages."
The money raised will help more than 5,000 young cancer patients
currently receiving care from St. Jude - all at no cost to their families.
The gala kicks off at 6:00 p.m. for a cocktail reception and silent auction
in which guests can bid on items including a shopping spree at Saks Fifth
Avenue and dinner for ten with artist Romero Britto. The ceremony will
include testimonials by St. Jude patient survivors, live performances and
an elegant dinner.
"FedEx is thrilled to have the Estefan's join us in the critical
partnership with St. Jude. No place in the world does what St. Jude does
for children stricken with leukemia and other cancers," said Julio C.
Barrionuevo, Vice President of Finance, Planning and Engineering for
Federal Express, Latin America & Caribbean. Barrionuevo chairs the annual
drive, and FedEx has been the title sponsor of the Angel and Stars Gala
since its inception in 2002.
The Estefans join other top Latin artists and entertainers who have
supported the life-saving mission of St. Jude over the past few years,
including, Albita, Antonio Banderas, Barbara Bermudo, Giselle Blondet,
Romero Bitto, Cristian Castro, Rashel Diaz, Luis Enrique, Erika Ender, Jose
Feliciano, Luis Fonsi, Javier Garcia, Jeremias, Jose Jose, Fanny Lu,
Domenic Marte, Jorge Moreno, Eduardo Osorio, Francisco Paz, Carlos Ponce,
Neida Sandoval, Gilberto Santa Rosa, Sissi, Jimmy Smits, Gaby Spanic, and
the late Soraya.
"There are no words to describe how grateful we are for the generosity
that the Hispanic community has shown to St. Jude. You are not fundraisers
but lifesavers," said John P. Moses, Chief Executive Officer for ALSAC, the
fundraising organization of St. Jude. "We are especially thrilled to
welcome Emilio and Gloria Estefan to our St. Jude family and congratulate
them on this evening's honor."
Gala sponsors include FedEx Express, Stanford Financial Group,
Universal Music Latino, VISA International, Univision Radio, Anthony R.
Abraham Foundation, Maya, Southern Wine and Spirits of South Florida, Sea
Latino, The "M" Point, KPMG, Yahoo!Telemundo, Telefonica, DDB, Car Factory
Outlet, Lopez- Cantera Foundation, CB Richard Ellis, Coors Brewing Company,
Inktel Direct, Jefferson Lee Ford III Memorial Foundation, Zubi
Advertising, The Miami Herald, Ocean Drive en Espanol, Merrill Lynch, Leon
Medical Centers, and Grey Goose Vodka.
"I am delighted with the awareness our sponsors and other St. Jude
supporters have brought to the fight against childhood cancer. I am so
proud that I have been a part of this event since its inception in 2002,"
said Daisy Fuentes. "I can think of no better cause to support than the
mission of St. Jude. Founder Danny Thomas would be proud that South Florida
and the Latin community is fighting hard to ensure his vision is kept
alive."
To purchase tickets, become a sponsor or donate items for the gala,
please call 1-800-278-3383.
ABOUT ST. JUDE CHILDREN'S RESEARCH HOSPITAL
St. Jude Children's Research Hospital is internationally recognized for
its pioneering work in finding cures and saving children with cancer and
other catastrophic diseases. Founded by the late entertainer Danny Thomas
and based in Memphis, Tennessee. St. Jude freely shares its discoveries
with scientific and medical communities around the world. No family ever
pays for treatments not covered by insurance, and families without
insurance are never asked to pay. St. Jude is financially supported by
ALSAC, its fundraising organization. For more information, please visit
http://www.stjude.org .
See Also
benefit St. Jude
Live performances by Luis Fonsi, Jeremias, and Valeria Gastaldi
MIAMI, May 9 -- St. Jude Children's Research Hospital(R),
the world's premier pediatric cancer research and treatment center,
celebrates its sixth annual FedEx/St. Jude Angels & Stars Gala on Saturday,
May 17, at the Adrienne Arsht Center for the Performing Arts of Miami-Dade
County.
(Photo: http://www.newscom.com/cgi-bin/prnh/20080509/CLF029 )
Latin stars join Daisy Fuentes in honoring Emilio and Gloria Estefan
for their commitment to international healthcare, the local community and
their presence in the music and entertainment industry.
"We are overwhelmed with pride to be honored by such an esteemed
group," said Gloria Estefan. "We are especially grateful for the hospital's
life saving efforts throughout Latin America. The St. Jude International
Outreach Program offers hope for sick children and their families, and they
also share their medical knowledge with the doctors who treat these
children in their hometowns and villages."
The money raised will help more than 5,000 young cancer patients
currently receiving care from St. Jude - all at no cost to their families.
The gala kicks off at 6:00 p.m. for a cocktail reception and silent auction
in which guests can bid on items including a shopping spree at Saks Fifth
Avenue and dinner for ten with artist Romero Britto. The ceremony will
include testimonials by St. Jude patient survivors, live performances and
an elegant dinner.
"FedEx is thrilled to have the Estefan's join us in the critical
partnership with St. Jude. No place in the world does what St. Jude does
for children stricken with leukemia and other cancers," said Julio C.
Barrionuevo, Vice President of Finance, Planning and Engineering for
Federal Express, Latin America & Caribbean. Barrionuevo chairs the annual
drive, and FedEx has been the title sponsor of the Angel and Stars Gala
since its inception in 2002.
The Estefans join other top Latin artists and entertainers who have
supported the life-saving mission of St. Jude over the past few years,
including, Albita, Antonio Banderas, Barbara Bermudo, Giselle Blondet,
Romero Bitto, Cristian Castro, Rashel Diaz, Luis Enrique, Erika Ender, Jose
Feliciano, Luis Fonsi, Javier Garcia, Jeremias, Jose Jose, Fanny Lu,
Domenic Marte, Jorge Moreno, Eduardo Osorio, Francisco Paz, Carlos Ponce,
Neida Sandoval, Gilberto Santa Rosa, Sissi, Jimmy Smits, Gaby Spanic, and
the late Soraya.
"There are no words to describe how grateful we are for the generosity
that the Hispanic community has shown to St. Jude. You are not fundraisers
but lifesavers," said John P. Moses, Chief Executive Officer for ALSAC, the
fundraising organization of St. Jude. "We are especially thrilled to
welcome Emilio and Gloria Estefan to our St. Jude family and congratulate
them on this evening's honor."
Gala sponsors include FedEx Express, Stanford Financial Group,
Universal Music Latino, VISA International, Univision Radio, Anthony R.
Abraham Foundation, Maya, Southern Wine and Spirits of South Florida, Sea
Latino, The "M" Point, KPMG, Yahoo!Telemundo, Telefonica, DDB, Car Factory
Outlet, Lopez- Cantera Foundation, CB Richard Ellis, Coors Brewing Company,
Inktel Direct, Jefferson Lee Ford III Memorial Foundation, Zubi
Advertising, The Miami Herald, Ocean Drive en Espanol, Merrill Lynch, Leon
Medical Centers, and Grey Goose Vodka.
"I am delighted with the awareness our sponsors and other St. Jude
supporters have brought to the fight against childhood cancer. I am so
proud that I have been a part of this event since its inception in 2002,"
said Daisy Fuentes. "I can think of no better cause to support than the
mission of St. Jude. Founder Danny Thomas would be proud that South Florida
and the Latin community is fighting hard to ensure his vision is kept
alive."
To purchase tickets, become a sponsor or donate items for the gala,
please call 1-800-278-3383.
ABOUT ST. JUDE CHILDREN'S RESEARCH HOSPITAL
St. Jude Children's Research Hospital is internationally recognized for
its pioneering work in finding cures and saving children with cancer and
other catastrophic diseases. Founded by the late entertainer Danny Thomas
and based in Memphis, Tennessee. St. Jude freely shares its discoveries
with scientific and medical communities around the world. No family ever
pays for treatments not covered by insurance, and families without
insurance are never asked to pay. St. Jude is financially supported by
ALSAC, its fundraising organization. For more information, please visit
http://www.stjude.org .
See Also
Subscribe to:
Posts (Atom)